Tina Gregg
NP-C
Location : Flowood, MS, USA
BIO
Tina Marie Gregg, NP-C, is a board-certified nurse practitioner specializing in gastroenterology with a particular focus on liver disease. She serves as The Liver Clinic Specialist at GI Associates & Endoscopy Center in Flowood, Mississippi, where she provides comprehensive care for patients with conditions such as cirrhosis, fatty liver disease, hepatitis, and other chronic liver disorders. Tina earned her Master of Science in Nursing degree from University of Mississippi Medical Center and has been certified by the American Academy of Nurse Practitioners since 2007. At GI Associates, she is actively involved in clinical care, coordinating diagnostic evaluations, treatment plans, and long-term disease management. She also serves as a Sub-investigator within the Research Department. Known for her compassionate and thorough approach, Tina is dedicated to helping patients understand their conditions and treatment options while ensuring close follow-up and ongoing support.
MASLD-MASH Content Featuring Tina
Webcast: MASLD Pharmacotherapy With Tina Gregg
November 2025
In this educational presentation, Tina Gregg, NP-C breaks down the evolving pharmacotherapy landscape for MASLD and MASH, emphasizing a holistic, metabolic-centered approach to patient management. Tina reviews key treatment pillars—including weight loss, cardiovascular risk reduction, and direct NASH-targeted therapy—highlighting evidence-based strategies such as lifestyle modification, GLP-1 receptor agonists, pioglitazone, vitamin E, and the first FDA-approved therapy for MASH with F2–F3 fibrosis, resmetirom. She explains how these interventions improve hepatic histology, reduce fibrosis, and address comorbidities like diabetes and obesity. The session also explores data from the MAESTRO-NASH trial, drug-drug interaction considerations, and ongoing monitoring guidance for resmetirom. Whether you’re managing patients in hepatology, GI, or primary care, this discussion offers a comprehensive overview of current and emerging medical therapies shaping the future of metabolic liver disease care.
Watch Now
Common Questions From Community GI About MASH
October 2025
In this APP Insight, Tina Gregg, NP-C, from GI Associates, addresses two of the most common questions about MASLD and MASH that clinicians encounter in practice. First, she clarifies that normal liver enzymes do not rule out MASH or advanced fibrosis—up to half of biopsy-proven cases can present with normal ALT and AST levels. Tina explains why liver enzymes fluctuate, why traditional reference ranges may be misleading, and how clinicians can better interpret lab results in context. She also answers another frequent question: Are statins safe in patients with MASLD or MASH? Drawing on evidence from multiple large studies, Tina emphasizes that statins are both safe and beneficial for most patients with fatty liver disease and play a key role in managing cardiovascular risk. This session, part of the GHAPP MASLD & MASH Community Network, helps APPs dispel common misconceptions and make evidence-based decisions in liver and metabolic care.
Watch Now
Diet and Nutrition: Tailoring Plans For Diverse Populations
October 2025
In this presentation, Tina Gregg, NP-C, from GI Associates, shares practical, evidence-based strategies for nutrition and lifestyle management in MASLD and MASH. With nearly two decades of experience caring for patients with liver disease, Tina emphasizes that lasting improvement requires more than telling patients to “lose weight”—it calls for tailored, culturally sensitive, and sustainable dietary guidance. She explores data supporting the Mediterranean diet, DASH diet, low- and moderate-carbohydrate approaches, intermittent fasting, and plant-based eating, detailing how each can reduce liver fat, improve insulin sensitivity, and decrease inflammation. Tina also discusses how to adapt these principles for patients’ cultural preferences, socioeconomic barriers, and comorbidities such as diabetes, CKD, and hyperlipidemia. This session, part of the GHAPP MASLD & MASH Community Network, highlights how APPs can guide patients toward realistic dietary changes that enhance both liver and metabolic health.
Watch Now
Webcast: Non-Invasive Testing With Tina Gregg
October 2025
In this session, Tina Gregg, NP-C, reviews non-invasive testing (NITs) for MASLD and MASH, using a real-world case to show how to assess risk and stage fibrosis without biopsy. Learn when to use FIB-4, ELF, FibroScan (VCTE), and MR elastography, how to interpret cutoffs, and when to refer to hepatology. Practical takeaways include triaging indeterminate FIB-4 results, recognizing test limitations, and counseling patients on lifestyle and follow-up. Presented via the GHAPP MASLD Community Network.
Watch Now
Management of Lifestyle Modification
January 2025
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Third Step of Lifestyle Management
January 2025
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
Approved Medication for MASH/NASH
January 2025
This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.
Watch Now
Types of Diet for the Treatment of MASLD
January 2025
This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.
Watch Now
NITs to Identify High Risk MASH Patients
January 2025
Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.
Watch Now
Click the arrows to view more content
